Thyroid hormone resistance with succinate dehydrogenase-B gene mutation
View/ Open
Access
info:eu-repo/semantics/closedAccessDate
2022Author
Erel, CansuCakmak, Ramazan
Ullari, Hulya Hacisahinog
Artan, Selay
Ayse, Kubat Uzum
Aral, Ferihan
TANAKOl, Refik
Yazici, Hulya
Metadata
Show full item recordCitation
Erel, C., Cakmak, R., Ullari, H. H., Artan, S., Ayse, K. U., Aral, F., . . . Yazici, H. (2022). Thyroid hormone resistance with succinate dehydrogenase-B gene mutation. Minerva Endocrinology, 47(2), 137-139. doi:10.23736/S2724-6507.21.03602-2Abstract
Resistance to thyroid hormone (RTH) is characterized by non-suppressed TSH concentration despite high T4 and/or T3 levels.1 Resistance may develop at any steps in the hormone
receptor binding, signaling, or intracellular thyroid hormone metabolism process. The disease
is caused by mutations in the thyroid hormone
receptor beta (THRB) in the majority of cases.2
Mutations in other genes have been associated
with RTH, including thyroid hormone receptor
alpha (THRA), Monocarboxylate transporter-8
(MCT8), and selenocysteine insertion sequence
binding protein 2 (SECISBP2).2, 3 After clinical
and laboratory examinations, genetic screening
of other family members is necessary in suspicious cases. Succinate dehydrogenase subunit B
(SDHB) is a well-known gene related to pheochromocytoma and extra-adrenal paragangliomas in the head and neck.4-6 The patient as well
as his two children who have been diagnosed
with RTH, all are found to have SDHB mutations
that are functionally significant. This is the first
report an SDHB mutation has been recorded in
an RTH case in the medical literature. A 50-yearold man evaluated preoperatively for nasal surgery showed hyperthyroidism, and he was prescribed methimazole orally. An ultrasound of his
enlarged thyroid gland revealed a 13 mm haloed
cystic necrotic nodule. The nodule was diagnosed
as Bethesda IV suspicious for follicular neoplasia
after a fine-needle aspiration biopsy. His laboratory findings were FT3:13.7 pmol/L (3.1-6.8),
FT4: 20.5 pmol/L (12-22), and TSH:1.0 mIU/mL
(0.27-4.2). He was planned for a total thyroidectomy in the euthyroid state and referred to our department. He had mild hyperthyroid symptoms,
including excessive sweating and agitation. He
was shorter than the population’s average height.
He had a goiter and tachycardia on his physical
examination. On repeated testing, his laboratory
findings revealed a high FT3 level. Antibody interaction misleading results in polyethyleneglycol precipitated thyroid hormones were investigated, and comparable results were found. Scintigram and negative thyroid auto-antibodies ruled
out Graves’ disease. Normal anterior pituitary
hormone levels and a hypophysial MRI ruled out
a pituitary adenoma. Drug-induced hyperthyroidism and acute non-thyroidal disease were not
taken into consideration. His brother, his son, and
his daughter had incompatible thyroid hormone
concentrations as the index case (Table I).